For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Thoracic MRI Scan With 1.5 Tesla MRI | Subjects will be enrolled at least 60 days post successful St. Jude Medicalâ„¢ MR Conditional ICD System implant. Enrolled subjects will undergo an elective 1.5T MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit. | 2 | None | 1 | 205 | 1 | 205 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Breathlessness | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Refractory cardiogenic shock, recurrent ventricular tachycardia, ventricular fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Ventricular arrhythmia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Serious Adverse Device Effect: Acute Pulmonary Edema | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Loss of Capture | SYSTEMATIC_ASSESSMENT | Product Issues | None | View |